Company intelligence / Profile preview

Pebble Biosciences

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Pebble Biosciences is an early-stage biotechnology company focused on developing next-generation small molecule therapeutics for oncology. The company utilizes a proprietary platform designed to target complex protein-protein interactions (PPIs) that have historically been considered "undruggable." By leveraging advanced chemical biology and computational tools, Pebble Biosciences aims to discover novel inhibitors for high-value oncogenic drivers. The company is currently in the pre-clinical stage, advancing a pipeline of candidates aimed at addressing significant unmet needs in cancer treatment.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PBS-119

Unknown

Beyond the preview

Go deeper on Pebble Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pebble Biosciences.

Explore the full profile